POST 23rd_BEF
> ATTENDEES​​
> INVESTORS​
> PRESENTERS
​​> EXHIBITORS​​
> SPONSORS​​
> SUPPORTERS​​

SILVER SPONSORs

basel+

The Canton of Basel-Stadt contributes to the further development of convention-related tourism. Conventions are specifically acquired, developed and held, thus accessing a potential not yet exploited with benefits beyond tourism.

The objective of convention promotion is to increase the direct and indirect added value generated by conventions. Additionally, a further strengthening of Basel as the most innovative economic location and center of knowledge in Switzerland is targeted. By promoting conventions, we want to contribute to Basel remaining one of the most important trade fair and convention cities in Europe.

www.bs.ch/en/Portrait/cosmopolitan-basel.html

stifel

Stifel is a full-service investment bank, offering securities brokerage, trading, research, underwriting and corporate advisory services globally. Our expertise spans sectors and products in both public and private markets. We are driven by relationships, not transactions, and are committed to earning long-term trust from our clients. The breadth of our platform and experience of our people uniquely position us to provide a range of solutions with the ability to quickly pivot as client needs evolve.
 
We are pleased to welcome Torreya Partners to Stifel from 1 March 2023. Torreya adds a global investment banking boutique serving companies in the life sciences industry. Since its inception in 2007, Torreya have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies.

www.stifelinstitutional.com/global-coverage/europe/investment-banking/

---

Bronze sponsors

Invest Hong Kong

Invest Hong Kong is the Investment Agency for the Hong Kong Government. We are able to offer you a multitude of grants and tax incentives when doing R&D or Clinical Trials in Hong Kong as well as in-depth market research and unique business opportunities. We became the leading Biotech IPO Destination in Asia and related we would like to discuss with you how to proliferate your company within our hub. We are seeking promising biomedical companies inspired to conduct R&D works in Hong Kong within Infectious Diseases, CNS, Immune Disorders, Cardiovascular, Oncology, Digital Health and Medical AI.

www.investhk.gov.hk

Merck KGaA, Darmstadt, Germany

We are Merck KGaA, Darmstadt, Germany, a vibrant science and technology company.

Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.

The passion of our curious minds makes a positive difference to millions of people’s lives every day.

In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information.

Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live.

We are curious minds dedicated to human progress.

​www.merckgroup.com/en/company/partnering/collaboration/collaboration-in-healthcare/strategic-focus-and-partnerships.html

---

CONTRIBUTING SPONSOR

canton of basel-stadt

An economic powerhouse situated on the border of three countries, Basel-Stadt offers a very dynamic business environment. A healthy ecosystem thrives on its diversity to enrich and pollinate each other. Existing blue-chip companies, international companies that settle here, leading research institutes and SME’s rub shoulders with vibrant startups, prolific incubators and multinationals which thrive in the area. Born in the nucleus of life sciences innovation, Basel-Stadt flourishes as an international hub of innovation, culture and business acumen.
 
Switzerland is considered the most innovative country in the world, according to a number of studies. Access to knowledge, highly qualified and international talent and a supportive government have turned Basel into the leading innovation hub of Switzerland. A future-oriented outlook with continuous innovation marks Basel as an international leader in life sciences, healthcare, ICT technology and circular economy.

With a population of 200,000, Basel may seem to be a small city, but its rich economic and cultural offerings put it firmly in the big league. Many international companies and well-known brands such as Novartis, Roche, Lonza, Moderna, BeiGgene, Bayer and Syngenta have their headquarters here, and the city has a thriving, multi-cultural, well-educated expat community coming from more than 160 different countries.

www.wsu.bs.ch

Latham & Watkins LLP

Latham & Watkins LLP is one of the largest law firms in the world with more than 3,000 lawyers located in major financial, business and regulatory centers around the globe. Our award-winning Healthcare & Life Sciences Industry guides clients through their most significant and cutting-edge legal challenges through a combination of in-depth industry knowledge, legal acumen, and strategic business advice. We understand the unique economic, market, regulatory and political climates in which healthcare and life sciences companies operate.

www.lw.com/

NOVO HOLDINGS A/S

Novo Holdings is a holding and investment company, responsible for managing the operating and financial assets of the Novo Nordisk Foundation. Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes and manages an investment portfolio, with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of two teams, namely, Life Science Investments and Novo Capital Investors. We aspire to be a leading responsible investor, recognized for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of $106 billion. Novo Holdings is among the world’s leading life science investors and invests in companies at all stages of development. The Life Science Investments team includes Novo Seeds, Novo Ventures, Novo Growth and Principal Investments. In 2021 Life Science Investments invested $2.2 billion in 71 companies. The Novo Capital Investors team manages a broad portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments.


https://www.novoholdings.dk/

PharmaVentures Ltd.

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.

For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.

PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising Support
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuations (licensing, M&A and fundraising)
• Pricing and Market Access

PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit company’s website.

www.pharmaventures.com/